Trials / Terminated
TerminatedNCT04396574
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 566 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 6 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lasmiditan | Administered orally |
Timeline
- Start date
- 2020-06-30
- Primary completion
- 2025-12-04
- Completion
- 2025-12-04
- First posted
- 2020-05-20
- Last updated
- 2026-03-10
Locations
134 sites across 15 countries: United States, Belgium, Canada, France, Germany, India, Italy, Japan, Mexico, Netherlands, Puerto Rico, Romania, Russia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04396574. Inclusion in this directory is not an endorsement.